Department of Medical Oncology and INSERM U981, Institut Gustave Roussy, Villejuif, France.
Ann Oncol. 2012 Aug;23 Suppl 6:vi46-51. doi: 10.1093/annonc/mds195.
Triple-negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options and very poor prognosis following progression after standard chemotherapeutic regimens. Resistance to current standard therapies such as anthracyclines or taxanes limits the available options for previously treated patients with metastatic TNBC to a small number of non-cross-resistant regimens, and there is currently no preferred standard chemotherapy. Duration of response is usually short, with rapid relapse very common and median survival of just 13 months. The newly approved agent eribulin has shown a survival benefit in patients who had previously been treated with anthracycline- or taxane-containing regimens, including in patients with TNBC. Platinum-based regimens are an emerging option for patients with BRCA1 mutation, and newer targeted agents such as anti-angiogenic treatment with bevacizumab or anti-epidermal growth factor receptor treatment with cetuximab, have shown some benefit in combination therapy. However, there remains an urgent unmet need for improved targeted agents for this patient population. Improved treatment may be facilitated by biomarker-led understanding of subgroup molecular targets, which may predict benefit from currently approved agents, as well as newer targeted drugs.
三阴性乳腺癌（TNBC）是一种侵袭性组织学亚型，在标准化疗方案进展后，治疗选择有限，预后极差。对当前标准治疗（如蒽环类或紫杉类）的耐药性限制了转移性 TNBC 既往治疗患者的可用选择，只有少数非交叉耐药方案，目前尚无首选的标准化疗方案。缓解持续时间通常较短，迅速复发很常见，中位生存期仅为 13 个月。新批准的药物艾立布林在既往接受含蒽环类或紫杉类方案治疗的患者中显示出生存获益，包括 TNBC 患者。对于 BRCA1 突变的患者，铂类方案是一种新兴的选择，新型靶向药物，如贝伐珠单抗的抗血管生成治疗或西妥昔单抗的抗表皮生长因子受体治疗，在联合治疗中显示出一定的疗效。然而，对于这部分患者人群，仍迫切需要改善靶向药物。通过生物标志物指导的亚组分子靶点的理解，可以预测目前批准的药物以及新型靶向药物的获益，从而改善治疗。
